Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (381-390 of 418) with videos related to

Pageof 42
Sort By:
Journal of the American Academy of Dermatology|February 17, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapiesAlan Menter, Neil J Korman, Craig A Elmets, et al.
Journal of the American Academy of Dermatology|October 16, 2013
Research gaps in psoriasis: opportunities for future studiesCaitriona Ryan, Neil J Korman, Joel M Gelfand, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.
Journal of the American Academy of Dermatology|April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialAndrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
International Journal of Dermatology|January 31, 2025
Psoriasis in People With Skin of Color: An Evidence-Based UpdateMaria-Angeliki Gkini, Mio Nakamura, Andrew F Alexis, et al.
Pageof 42

Showing results (381-390 of 418) with videos related to

Sort By:
Pageof 42
Journal of the American Academy of Dermatology|February 17, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapiesAlan Menter, Neil J Korman, Craig A Elmets, et al.
Journal of the American Academy of Dermatology|October 16, 2013
Research gaps in psoriasis: opportunities for future studiesCaitriona Ryan, Neil J Korman, Joel M Gelfand, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.
Journal of the American Academy of Dermatology|April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialAndrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Lancet (London, England)|August 12, 2018
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trialsKenneth B Gordon, Bruce Strober, Mark Lebwohl, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
International Journal of Dermatology|January 31, 2025
Psoriasis in People With Skin of Color: An Evidence-Based UpdateMaria-Angeliki Gkini, Mio Nakamura, Andrew F Alexis, et al.
Pageof 42